Is it Rational,Reasonable or Excessive,and Consistently Applied? One View of the Increasing FDA Emphasis on Safety First for the Release and Use of Antiarrhythmic Drugs for Supraventricular Arrhythmias
Free accessOtherFirst published online December, 2001
Is it Rational,Reasonable or Excessive,and Consistently Applied? One View of the Increasing FDA Emphasis on Safety First for the Release and Use of Antiarrhythmic Drugs for Supraventricular Arrhythmias
1. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med321:406-412, 1989
2.
2. Teo KK, Yusuf S, Furberg CD.Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA270:1589-1595, 1993
3.
3. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet348:7-12, 1996
4.
4. McClellan KJ, Markham A.Dofetilide: A review of its use in atrial fibrillation and atrial flutter. Drugs58:1043-1059, 1999
5.
5. Singh SN, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation/flutter: The symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation102:2385-2390, 2000
6.
6. Greenbaum R, Campbell TJ, Channer KS, et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide: The EMERALD (European and Australian multicenter evaluative research of atrial fibrillation dofetilide) study [abstract]. Circulation98 (suppl 1):1-633, 1998
7.
7. Kassotis J, Costeas C, Blitzer M, Reiffel JA.Rhythm management in atrial fibrillation with a primary emphasis on pharmacologic therapy-Part 3. PACE21:1133-1145, 1998
8.
8. Reiffel JA.Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific data-driven decision. Am J Cardiol82:72N-8 IN, 1998
9.
9. Kober L, Bloch-Thomsen PE, Moller M, et al. Danish investigations of arrhythmia and mortality on dofetilide (DIAMOND) study group. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: A randomized trial. Lancet356:2052-2058, 2000
10.
10. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Effect of dofetilide on mortality and morbidity in congestive heart failure and left ventricular dysfunction: The DIAMOND-CHF Study. N Engl J Med341:857-865, 1999
11.
11. Mounsay JP, Di Marco JP.Cardiovascular drugs: Dofetilide. Circulation162:2665-2670, 2000
12.
12. Tikosyn Package Insert. Pfizer, New York, 2001
13.
13. Betapace AF Package Insert. Berlex Laboratories, Wayne, NJ, 2001
14.
14. Benditt DG, Williams HH, Jin J, et al. Maintenance of sinus rhythm with oral d,l-sotalol in patients with symptomatic atrial fibrillation and/or atrial flutter. Am J Cardiol84:270-277, 1999
15.
15. Reiffel JA.Inpatient versus outpatient antiarrhythmic drug initiation: Safety and cost-effective issues. Curr Opin Cardiol15:7-11, 2000
16.
16. Reiffel JA, Camm AJ, Haffajee CJ, et al. International consensus roundtable on atrial fibrillation. Cardiol Rev12 (suppl):1-19, 2000
17.
17. Julian DG, Prescott RJ, Jackson FS, Szekely P.Controlled trial of sotalol for one year after myocardial infarction. Lancet1:1142-1147, 1982
19. Clemett D, Markham A. Azimilide. Drugs59:271-277, 2000
20.
20. Pritchett EL, Page RL, Connolly SJ, Marcello SR, Schnell DJ, Wilkinson WE.Antiarrhythmic effects of azimilide in atrial fibrillation: Efficacy and dose-response. J Am Coll Cardiol36:794-802, 2000
21.
21. Abrol R, Page RL.Azimilide dihydrochloride: A new class III antiarrhythmic agent. Exp Opin Invest Drugs9:2705-2715, 2000
22.
22. Camm AJ, Karam R, Pratt CM.The azimilide post-infarct survival evaluation (ALIVE) trial. Am J Cardiol81: 35D-39D, 1998
23.
23. Reiffel JA.Issues in the use of generic antiarrhythmic drugs. Curr Opin Cardiol16:23-29, 2001
24.
24. Banahan BF, Kolassa EM.A physician survey on generic drugs and substitution of critical dose medications. Arch Intern Med157:2080-2088, 1997
25.
25. Anonymous. Physicians are concerued about generic drug bioequivalence, but often unaware of FDA standards. Am J Health System Pharmacy54:2799-2800, 1997
26.
26. Reiffel JA, Kowey PR.Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmias. Am J Cardiol85:1151-1152, 2000
27.
27. Grubb BP.Recurrence of ventricular tachycardia after conversion from proprietary to generic procainamide [published erratum, letter to editor in Am J Cardiol 67:334, 1991]. Am J Cardiol63:1532-1533, 1989
28.
28. Ozahowski TP, Greenberg MI, Mock RP.Clinical inequivalence of generic and brand name type IA antiarrhythmic drugs [abstract]. PACE21:809-809, 1998
